06/29/2017

CCN has published updates to the NCCN Guidelines® and the NCCN Compendium® for Ovarian Cancer

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and the NCCN Drugs & Biologics Compendium (NCCN Compendium^®) for Ovarian Cancer. These NCCN Guidelines^® are currently available as Version 2.2017. 

• Principles of Systemic Therapy, Acceptable Recurrence Therapies for Epithelial Ovarian Cancer Including Less Common Ovarian Histologies (LCOH)/Fallopian Tube/Primary Peritoneal Cancer (OV-B, 5/6 of 8)
  • Footnote "k" has been revised: In patients who have not previously received bevacizumab. There are limited data on the efficacy of bevacizumab in the recurrence therapy setting for patients previously treated with bevacizumab.
  • Footnote “m” has been added: "If response after chemotherapy, bevacizumab can be continued as maintenance therapy until disease progression or unacceptable toxicity." This footnote applies to the following recurrence therapy options for platinum-sensitive disease: Carboplatin/gemcitabine/bevacizumab, and carboplatin/paclitaxel/bevacizumab.

*For your reference, the previous update (Version 1.2017) to the NCCN Guidelines for Ovarian Cancer, published on April 12, 2017, is available at the following link: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf